What is the benefit of new combination regimens for the treatment of bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Newer combination regimens show response rates and median survival comparable to those for MVAC but with less toxicity. Gemcitabine plus cisplatin is now considered a first-line treatment for bladder cancer. Therapy with programmed cell death ligand 1 (PD-L1) inhibitors (eg, atezolizumab, nivolumab, durvalumab, avelumab, pembrolizumab) is now approved by the US Food and Drug Administration (FDA) for advanced urothelial carcinoma. Erdafitinib is the first fibroblast growth factor receptor (FGFR) inhibitor approved by the FDA for urothelial carcinoma, in April 2019. The first anti-nectin-4 monoclonal antibody, enfortumab vedotin, was approved for urothelial carcinoma in December 2019.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!